KalVista Pharmaceuticals (NASDAQ:KALV) Releases Earnings Results, Misses Expectations By $0.05 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), Zacks reports. The company had revenue of $39.16 million for the quarter, compared to analysts’ expectations of $39.14 million.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock traded down $0.01 on Friday, hitting $26.75. 5,581,597 shares of the company traded hands, compared to its average volume of 2,266,044. The firm’s 50-day simple moving average is $20.20 and its 200 day simple moving average is $16.65. KalVista Pharmaceuticals has a 12-month low of $9.83 and a 12-month high of $26.85. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The company has a market cap of $1.37 billion, a P/E ratio of -6.77 and a beta of -0.12.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Needham & Company LLC downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 30th. Finally, Stifel Nicolaus upped their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $30.60.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,686 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $54,310.92. Following the transaction, the insider directly owned 142,547 shares in the company, valued at $2,882,300.34. This trade represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $18.28, for a total transaction of $730,944.08. Following the completion of the sale, the insider owned 5,089,354 shares of the company’s stock, valued at approximately $93,033,391.12. The trade was a 0.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 263,937 shares of company stock valued at $4,572,251 over the last 90 days. Company insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently added to or reduced their stakes in KALV. BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $55,000. Truvestments Capital LLC lifted its holdings in KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of KalVista Pharmaceuticals by 816.8% in the second quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after purchasing an additional 7,180 shares during the period. Finally, Sei Investments Co. bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth approximately $145,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.